



PHARMACEUTICAL 2022

Emergent BioSolutions Inc. Rank 47 of 475



EMERGENT







PHARMACEUTICAL 2022

RealRate

Emergent BioSolutions Inc. Rank 47 of 475

The relative strengths and weaknesses of Emergent BioSolutions Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Emergent BioSolutions Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 373% points. The greatest weakness of Emergent BioSolutions Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 132% points.

The company's Economic Capital Ratio, given in the ranking table, is 127%, being 404% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	1,272,100
Cost of Goods Sold	0
Intangible Assets	829,500
Liabilities, Current	373,800
Liabilities, Non-Current	866,800
Other Assets	57,300
Other Compr. Net Income	9,200
Other Expenses	941,200
Other Liabilities	99,400
Other Net Income	-38,200
Property and Equipment	800,100
Research and Development	234,000
Revenues	1,792,700
Selling, General and Administrative Expense	348,400

Output Variable	Value in 1000 USD
Assets	2,959,000
Liabilities	1,340,000
Expenses	1,523,600
Stockholders Equity	1,619,000
Net Income	230,900
Comprehensive Net Income	235,500
Economic Capital Ratio	127%

